Arcturus Therapeutics Holdings Inc.

ARCT

Arcturus Therapeutics Holdings Inc.

ARCT

Insider Sentiment (TTM):

Last Purchase:2025-08-15Last Sale:2024-10-15Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:23,599,514Shares Outstanding:28,421,000Institutional Ownership Pct.:83.04%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	191	211	231	180	196	217	237	237	260	288	292	312
Restricted Cash Current	0	0	-	55	55	39	55	55	55	55	-	-
Restricted Cash	-	-	-	-	-	-	55	55	55	55	55	35
Accounts Receivable Net Current	2	1	6	8	17	15	4	30	24	27	32	38
Assets Current	197	217	241	249	275	279	306	331	347	376	387	393
Property Plant And Equipment Net	5	6	7	7	8	9	10	10	11	12	12	13
Operating Lease Right Of Use Asset	20	20	21	24	25	26	27	28	29	29	29	30
Restricted Cash Noncurrent	2	2	2	2	2	18	2	2	2	2	2	22
Assets	224	245	271	282	309	332	344	371	389	419	429	458
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	4	4	4	5	11	6	7	10	14	9	5	18
Accrued Liabilities Current	23	23	24	19	25	31	39	32	35	35	32	29
Deferred Revenue Current	6	8	8	7	11	13	20	27	42	72	45	41
Liabilities Current	34	34	36	32	47	49	65	69	92	115	82	88
Deferred Revenue Noncurrent	-	-	-	4	9	10	13	13	11	12	42	42
Operating Lease Liability Noncurrent	19	20	21	22	23	24	25	26	27	28	26	27
Other Liabilities Noncurrent	-	-	-	-	-	-	-	-	-	-	0	1
Liabilities	53	54	57	58	78	98	103	109	130	155	151	178
Stockholders Equity
Long Term Debt Noncurrent	-	-	-	-	-	15	-	-	-	-	-	20
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	737	733	729	710	703	697	690	681	670	659	646	636
Retained Earnings Accumulated Deficit	-565	-542	-515	-486	-472	-463	-449	-419	-412	-395	-368	-356
Stockholders Equity	172	191	214	225	231	234	241	262	259	264	279	280
Liabilities And Stockholders Equity	224	245	271	282	309	332	344	371	389	419	429	458
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	60	60	60	60	60	60	60	60	60	60	60	60
Common Stock Shares Issued	28	28	28	27	27	27	27	27	27	27	27	27
Shares Outstanding	28	28	28	27	27	-	27	27	27	27	27	27

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-11.01%	-22.70%	-37.87%	-	-	-	-	-	-	-	-	-
2025	10.35%	18.90%	6.13%	56.72%	98.07%	-12.47%	-12.30%	-23.12%	-8.12%	-14.54%	8.60%	-11.13%
2024	42.63%	-10.51%	-11.54%	6.62%	11.32%	-4.24%	-2.13%	-9.18%	-8.64%	-27.49%	-19.16%	-23.61%
2023	-	-	-	-0.35%	-19.78%	-42.20%	22.63%	60.98%	78.97%	-12.10%	-25.02%	6.71%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	5.88	6.31	6.64	7.86	5.90	5.64	4.67	4.76	3.78	3.26	4.72	4.49
Quick Ratio	5.88	6.31	6.64	7.86	5.90	5.64	4.67	4.76	3.78	3.26	4.72	4.49
Working Capital	163.63M	182.51M	205.07M	217.50M	227.99M	229.39M	240.49M	261.36M	255.29M	260.36M	304.60M	305.59M
Leverage & Debt
Debt to Equity	0.31	0.28	0.27	0.26	0.34	0.42	0.43	0.42	0.50	0.59	0.54	0.63
Debt Ratio	0.23	0.22	0.21	0.20	0.25	0.30	0.30	0.29	0.33	0.37	0.35	0.39
Efficiency & Turnover
Asset Turnover TTM	0.11	0.19	0.27	0.30	0.35	0.38	0.39	0.39	0.40	0.28	0.38	0.79
Days Sales Outstanding TTM	118.18	53.09	21.22	71.34	61.70	52.88	43.18	77.85	29.94	175.19	38.11	24.81
Receivables Turnover TTM	3.09	6.88	17.20	5.12	5.92	6.90	8.45	4.69	12.19	2.08	9.58	14.71
Per Share Metrics
Diluted EPS TTM	-3.28	-2.77	-2.40	-2.45	-2.22	-2.52	-3.00	-2.31	-2.67	-3.99	-1.12	3.74
Free Cash Flow Per Share TTM	-3.12	-2.07	-2.73	-0.87	-1.11	-3.32	-2.24	-2.28	-2.64	0.36	-0.79	5.15
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-348.32%	-161.52%	-92.96%	-80.27%	-59.43%	-57.13%	-62.81%	-50.22%	-54.39%	-99.07%	-46.89%	20.77%
Net Profit Margin TTM	-317.61%	-143.80%	-80.19%	-68.35%	-49.27%	-47.47%	-53.14%	-39.05%	-43.92%	-86.16%	-17.82%	33.53%
Growth Metrics
Net Revenue Growth (1Y)	-75.95%	-61.92%	-46.14%	-39.15%	-25.47%	15.38%	-8.69%	-45.85%	-38.04%	-55.69%	-19.03%	475.22%
Net Income Growth (1Y)	55.04%	15.35%	-18.73%	6.49%	-16.39%	-36.44%	172.30%	-163.07%	-189.63%	-196.43%	-417.95%	-167.73%
EPS Growth (1Y)	47.98%	10.02%	-19.87%	6.00%	-16.89%	-36.97%	168.55%	-161.93%	-188.29%	-195.26%	-415.76%	-167.45%
Valuation Metrics
P/E TTM	-2.05	-2.79	-2.55	-7.51	-5.87	-4.21	-5.66	-10.03	-9.12	-8.46	-28.24	6.84
P/B TTM	1.11	1.15	0.78	2.23	1.53	1.23	1.90	2.40	2.54	3.44	3.01	2.42
P/S TTM	6.50	4.01	2.05	5.13	2.89	2.00	3.01	3.92	4.01	7.29	5.03	2.29
Market Cap	191.00M	219.41M	167.88M	501.07M	352.95M	287.06M	458.19M	628.11M	656.65M	907.70M	839.58M	678.97M
Enterprise Value	-2.51M	6.01M	-64.92M	263.83M	99.60M	28.23M	164.28M	334.05M	339.43M	562.42M	490.69M	329.91M
Calculated Values
Free Cash Flow TTM	-88.66M	-58.94M	-74.78M	-23.65M	-30.16M	-89.87M	-60.40M	-61.62M	-71.16M	9.77M	-21.00M	136.96M
Net Debt	-193.51M	-213.40M	-232.79M	-237.25M	-253.35M	-258.83M	-293.91M	-294.06M	-317.21M	-345.28M	-348.89M	-349.05M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-08-15Purchase

Owner: Sassine, Andy

Title: Chief Financial Officer

Shares: 1,238

Price/Share: $16.56

Value: $20,501.28

Shares Owned: 221,764

Relationship: Director,Officer

Ownership: Direct

2024-10-15Sale

Owner: Chivukula, Pad

Title: Chief Scientific Officer & COO

Shares: 12,000

Price/Share: $20.76

Value: $249,120.00

Shares Owned: 435,334

Relationship: Officer

Ownership: Direct

2024-06-12Sale

Owner: Sassine, Andy

Title: Chief Financial Officer

Shares: 50,000

Price/Share: $32.03

Value: $1,601,500.00

Shares Owned: 220,526

Relationship: Director,Officer

Ownership: Direct

2024-06-05Sale

Owner: Chivukula, Pad

Title: Chief Scientific Officer & COO

Shares: 114

Price/Share: $45.00

Value: $5,130.00

Shares Owned: 447,334

Relationship: Officer

Ownership: Direct

2024-06-03Sale

Owner: Chivukula, Pad

Title: Chief Scientific Officer & COO

Shares: 26,000

Price/Share: $40.01

Value: $1,040,260.00

Shares Owned: 447,448

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-08-15	Sassine, Andy	Director,Officer	Chief Financial Officer	Direct	Purchase	1,238	16.56	$20,501.28	221,764	4/A
2024-10-15	Chivukula, Pad	Officer	Chief Scientific Officer & COO	Direct	Sale	12,000	20.76	$249,120.00	435,334	4
2024-06-12	Sassine, Andy	Director,Officer	Chief Financial Officer	Direct	Sale	50,000	32.03	$1,601,500.00	220,526	4
2024-06-05	Chivukula, Pad	Officer	Chief Scientific Officer & COO	Direct	Sale	114	45.00	$5,130.00	447,334	4
2024-06-03	Chivukula, Pad	Officer	Chief Scientific Officer & COO	Direct	Sale	26,000	40.01	$1,040,260.00	447,448	4
2024-03-25	Chivukula, Pad	Officer	Chief Scientific Officer & COO	Direct	Sale	17,435	35.02	$610,573.70	473,448	4
2024-03-19	Chivukula, Pad	Officer	Chief Scientific Officer & COO	Direct	Sale	8,565	35.01	$299,860.65	490,883	4
2023-11-01	Chivukula, Pad	Officer	Chief Scientific Officer & COO	Direct	Sale	5,000	18.72	$93,600.00	499,448	4
2023-10-02	Chivukula, Pad	Officer	Chief Scientific Officer & COO	Direct	Sale	5,000	25.61	$128,050.00	504,448	4
2023-09-01	Chivukula, Pad	Officer	Chief Scientific Officer & COO	Direct	Sale	5,000	31.45	$157,250.00	509,448	4
2023-08-01	Chivukula, Pad	Officer	Chief Scientific Officer & COO	Direct	Sale	5,000	34.91	$174,550.00	514,448	4
2023-07-14	Kummerfeld, Keith C	Officer	See Remarks	Direct	Sale	6,968	35.00	$243,880.00	950	4
2023-07-14	Chivukula, Pad	Officer	Chief Scientific Officer & COO	Direct	Sale	25,000	35.01	$875,250.00	519,448	4
2023-07-03	Chivukula, Pad	Officer	Chief Scientific Officer & COO	Direct	Sale	5,000	28.75	$143,750.00	544,448	4
2023-06-01	Chivukula, Pad	Officer	Chief Scientific Officer & COO	Direct	Sale	5,000	27.16	$135,800.00	549,448	4
2023-05-11	Chivukula, Pad	Officer	Chief Scientific Officer & COO	Direct	Sale	7,925	30.24	$239,652.00	554,448	4
2023-05-01	Chivukula, Pad	Officer	Chief Scientific Officer & COO	Direct	Sale	5,000	25.93	$129,650.00	579,448	4
2023-04-18	Kummerfeld, Keith C	Officer	See Remarks	Direct	Sale	6,968	28.18	$196,358.24	950	4
2023-04-03	Chivukula, Pad	Officer	Chief Scientific Officer & COO	Direct	Sale	5,000	25.38	$126,900.00	584,448	4
2023-03-06	Chivukula, Pad	Officer	Chief Scientific Officer & COO	Direct	Sale	5,000	16.07	$80,350.00	589,448	4
2022-12-15	Marquet, Magda	Director	-	Indirect	Purchase	2,222	18.00	$39,996.00	24,942	4
2022-11-23	Payne, Joseph E	Director,Officer	President and CEO	Direct	Purchase	5,000	16.51	$82,550.00	1,480,097	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

83.04%

Inst. Shares: 23,599,514

Shares Outstanding: 28,421,000

2025-12-31

84.43%

Inst. Shares: 23,121,552

Shares Outstanding: 27,386,000

2025-09-30

93.16%

Inst. Shares: 25,327,351

Shares Outstanding: 27,188,000

2025-06-30

93.35%

Inst. Shares: 25,324,483

Shares Outstanding: 27,129,000

2025-03-31

96.99%

Inst. Shares: 26,290,403

Shares Outstanding: 27,107,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	23,599,514	28,421,000	83.04%
2025-12-31	23,121,552	27,386,000	84.43%
2025-09-30	25,327,351	27,188,000	93.16%
2025-06-30	25,324,483	27,129,000	93.35%
2025-03-31	26,290,403	27,107,000	96.99%
2024-12-31	26,427,445	27,000,000	97.88%
2024-09-30	25,996,967	27,062,000	96.06%
2024-06-30	25,981,702	26,967,000	96.35%
2024-03-31	26,885,580	26,879,000	100.02%
2023-12-31	25,022,106	26,628,000	93.97%
2023-09-30	24,539,879	26,574,000	92.35%
2023-06-30	22,841,431	26,563,000	85.99%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Arcturus Therapeutics Holdings Inc. (ARCT) — SEC Financial Statements & Analysis

Arcturus Therapeutics Holdings Inc. (ARCT) is a pharmaceutical preparations company, incorporated in DE. Arcturus Therapeutics Holdings Inc. trades on Nasdaq as: ARCT. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Arcturus Therapeutics Holdings Inc. reported a -75.95% year-over-year revenue growth, a Debt-to-Equity ratio of 0.31x, a Price-to-Sales (P/S) ratio of 6.50x (TTM), a Price-to-Book (P/B) ratio of 1.11x (TTM), at a market cap of $191.00M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -75.95%
Debt To Equity: 0.31x
P/S TTM: 6.50x
P/B TTM: 1.11x
Market Cap: $191.00M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Arcturus Therapeutics Holdings Inc. in?

Arcturus Therapeutics Holdings Inc. (ARCT) operates in the Pharmaceutical Preparations industry.

What is ARCT's market cap?

Arcturus Therapeutics Holdings Inc. (ARCT) has a market capitalization of $191.00M as of 2026-06-30.

What exchange does ARCT trade on?

Arcturus Therapeutics Holdings Inc. (ARCT) trades on the Nasdaq.

Where is Arcturus Therapeutics Holdings Inc. incorporated?

Arcturus Therapeutics Holdings Inc. is incorporated in DE.